Answer
Cobicistat blocks CYP3A metabolism and increases elvitegravir exposure. It is a pharmacokinetic enhancer rather than an antiviral agent.
Sources for this answer
- Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead 90 mg/90 mg/120 mg/6 mg film coated tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.